Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1999 Jan 12;160(1):49–57.

Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen

M D Krahn 1, A Coombs 1, I G Levy 1
PMCID: PMC1229945  PMID: 9934343

Abstract

BACKGROUND: Concern over the cost of screening for asymptomatic prostate cancer by means of prostate-specific antigen (PSA) testing has played an important role in PSA screening policy. However, little is known about the true costs of current PSA screening in Canada and how costs may change in the future. METHODS: The authors performed a cost identification study from the perspective of provincial ministries of health. They used data from published reports, hospital discharge data, claims data from several provinces, a laboratory survey, a national survey of knowledge, attitudes and beliefs about screening, a provincial cancer registry and expert opinion to estimate current first-year screening costs. Using demographic data from Statistics Canada and various scenarios regarding changes in screening patterns, the authors derived estimates of the future costs of PSA screening. RESULTS: In 1995 PSA screening cost an estimated $45 million (range $40 million to $84 million). Treatment accounted for over 61% of total costs, whereas screening, diagnosis and staging accounted for 35%. Screening all eligible men in Canada in 1995 would have cost $317 million (range $356 million to $691 million), more than the costs of all prostate cancer care in that year. Annual recurrent screening for all eligible men in 2005 would cost $219 million (range $208 million to $412 million). Projections from existing trends suggest that annual costs of PSA screening in 2000 are likely to increase from the estimated $45 million to approximately $66 million (range $59 million to $126 million). INTERPRETATION: PSA screening is costly, but even universal screening would consume a smaller share of national health expenditures than previous studies have suggested. Costs attributable to PSA screening may increase in the future owing to changes in utilization patterns and demographic shifts.

Full Text

The Full Text of this article is available as a PDF (148.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bunting P. S., Miyazaki J. H., Goel V. Laboratory survey of prostate specific antigen testing in Ontario. Clin Biochem. 1998 Feb;31(1):47–49. doi: 10.1016/s0009-9120(97)00141-0. [DOI] [PubMed] [Google Scholar]
  2. Carlsson P., Hjertberg H., Jönsson B., Varenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol. 1989;23(2):93–96. doi: 10.3109/00365598909180819. [DOI] [PubMed] [Google Scholar]
  3. Catalona W. J., Smith D. S., Ratliff T. L., Basler J. W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993 Aug 25;270(8):948–954. [PubMed] [Google Scholar]
  4. Coley C. M., Barry M. J., Fleming C., Fahs M. C., Mulley A. G. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med. 1997 Mar 15;126(6):468–479. doi: 10.7326/0003-4819-126-6-199703150-00010. [DOI] [PubMed] [Google Scholar]
  5. Cooper B. S., Rice D. P. The economic cost of illness revisited. Soc Secur Bull. 1976 Feb;39(2):21–36. [PubMed] [Google Scholar]
  6. Detsky A. S., Naglie I. G. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990 Jul 15;113(2):147–154. doi: 10.7326/0003-4819-113-2-147. [DOI] [PubMed] [Google Scholar]
  7. Dorr V. J., Williamson S. K., Stephens R. L. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med. 1993 Nov 22;153(22):2529–2537. [PubMed] [Google Scholar]
  8. Eisenberg J. M. Clinical economics. A guide to the economic analysis of clinical practices. JAMA. 1989 Nov 24;262(20):2879–2886. doi: 10.1001/jama.262.20.2879. [DOI] [PubMed] [Google Scholar]
  9. Fowler F. J., Jr, Barry M. J., Lu-Yao G., Wasson J., Roman A., Wennberg J. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology. 1995 Jun;45(6):1007–1015. doi: 10.1016/s0090-4295(99)80122-8. [DOI] [PubMed] [Google Scholar]
  10. Gurwitz J. H., Avorn J., Bohn R. L., Glynn R. J., Monane M., Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994 Sep 14;272(10):781–786. [PubMed] [Google Scholar]
  11. Hodgson T. A. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res. 1983;4:129–164. [PubMed] [Google Scholar]
  12. Koopmanschap M. A., van Roijen L., Bonneux L., Barendregt J. J. Current and future costs of cancer. Eur J Cancer. 1994;30A(1):60–65. doi: 10.1016/s0959-8049(05)80020-6. [DOI] [PubMed] [Google Scholar]
  13. Krahn M. D., Berka C., Langlois P., Detsky A. S. Direct and indirect costs of asthma in Canada, 1990. CMAJ. 1996 Mar 15;154(6):821–831. [PMC free article] [PubMed] [Google Scholar]
  14. Kramer B. S., Brown M. L., Prorok P. C., Potosky A. L., Gohagan J. K. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993 Nov 1;119(9):914–923. doi: 10.7326/0003-4819-119-9-199311010-00009. [DOI] [PubMed] [Google Scholar]
  15. Labrie F., Candas B., Cusan L., Gomez J. L., Diamond P., Suburu R., Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology. 1996 Feb;47(2):212–217. doi: 10.1016/S0090-4295(99)80419-1. [DOI] [PubMed] [Google Scholar]
  16. Laupacis A., Feeny D., Detsky A. S., Tugwell P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 Feb 15;146(4):473–481. [PMC free article] [PubMed] [Google Scholar]
  17. Levy I. Prostate cancer: the epidemiologic perspective. Can J Oncol. 1994 Nov;4 (Suppl 1):4–7. [PubMed] [Google Scholar]
  18. Lu-Yao G. L., McLerran D., Wasson J., Wennberg J. E. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993 May 26;269(20):2633–2636. doi: 10.1001/jama.269.20.2633. [DOI] [PubMed] [Google Scholar]
  19. Mercer S. L., Goel V., Levy I. G., Ashbury F. D., Iverson D. C., Iscoe N. A. Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions. Can J Public Health. 1997 Sep-Oct;88(5):327–332. doi: 10.1007/BF03403900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mettlin C., Murphy G. P., Babaian R. J., Chesley A., Kane R. A., Littrup P. J., Mostofi F. K., Ray P. S., Shanberg A. M., Toi A. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1996 Jan 1;77(1):150–159. doi: 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  21. Moore R., Mao Y., Zhang J., Clarke K. Economic burden of illness in Canada, 1993. Executive summary and recommendations. Chronic Dis Can. 1997;18(2):95–96. [PubMed] [Google Scholar]
  22. Optenberg S. A., Thompson I. M. Economics of screening for carcinoma of the prostate. Urol Clin North Am. 1990 Nov;17(4):719–737. [PubMed] [Google Scholar]
  23. Pink G. H., Bolley H. B. Physicians in health care management: 3. Case Mix Groups and Resource Intensity Weights: an overview for physicians. CMAJ. 1994 Mar 15;150(6):889–894. [PMC free article] [PubMed] [Google Scholar]
  24. Pink G. H., Bolley H. B. Physicians in health care management: 4. Case Mix Groups and Resource Intensity Weights: physicians and hospital funding. CMAJ. 1994 Apr 15;150(8):1255–1261. [PMC free article] [PubMed] [Google Scholar]
  25. Potosky A. L., Miller B. A., Albertsen P. C., Kramer B. S. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995 Feb 15;273(7):548–552. [PubMed] [Google Scholar]
  26. Robinson J. C. Philosophical origins of the economic valuation of life. Milbank Q. 1986;64(1):133–155. [PubMed] [Google Scholar]
  27. Schwartz K. L., Severson R. K., Gurney J. G., Montie J. E. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994. Cancer. 1996 Sep 15;78(6):1260–1266. doi: 10.1002/(SICI)1097-0142(19960915)78:6<1260::AID-CNCR14>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  28. Smith D. S., Catalona W. J., Herschman J. D. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996 Oct 23;276(16):1309–1315. [PubMed] [Google Scholar]
  29. Smith D. S., Catalona W. J., Herschman J. D. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996 Oct 23;276(16):1309–1315. [PubMed] [Google Scholar]
  30. Stephenson R. A., Smart C. R., Mineau G. P., James B. C., Janerich D. T., Dibble R. L. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry. Cancer. 1996 Apr 1;77(7):1342–1348. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1342::AID-CNCR18>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  31. Tugwell P., Bennett K. J., Sackett D. L., Haynes R. B. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis. 1985;38(4):339–351. doi: 10.1016/0021-9681(85)90080-3. [DOI] [PubMed] [Google Scholar]
  32. Warde P., Murphy T. Measuring the cost of palliative radiotherapy. Can J Oncol. 1996 Feb;6 (Suppl 1):90–94. [PubMed] [Google Scholar]
  33. Wasson J. H., Cushman C. C., Bruskewitz R. C., Littenberg B., Mulley A. G., Jr, Wennberg J. E. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993 May;2(5):487–493. doi: 10.1001/archfami.2.5.487. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES